ciforadenant
Small moleculeexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT02655822)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Healthy Volunteers · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Multiple Myeloma · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms, Castration-Resistant · Phase 1
- Sarcoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- Alpha-2a adrenergic receptorANTAGONIST
ADRA2A antagonist
- Adenosine A2a receptorANTAGONIST
Adenosine A2a receptor antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(-c2nc(N)nc3c2nnn3Cc2cccc(CO[C@H]3CCOC3)n2)o1- Mol. weight
- 407.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297184 ↗
Also known as
- cpi-444
- cpi-444
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05501054 | Phase 1/Phase 2 (Phase 2) | Feb 28, 2023 | University of Texas at Houston |
| NCT04280328 | Phase 1 | Feb 28, 2020 | Corvus Pharmaceuticals, Inc. |
| NCT03454451 | Phase 1 | Apr 25, 2018 | Corvus Pharmaceuticals, Inc. |
| NCT03337698 | Phase 1/Phase 2 (Phase 2) | Dec 27, 2017 | Roche |
| NCT03237988 | Phase 1 | Jul 20, 2017 | Corvus Pharmaceuticals, Inc. |
| NCT02655822 | Phase 1 | Jan 1, 2016 | Corvus Pharmaceuticals, Inc., Genentech |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | For profit | 4 | 4 | 1 | 2016 |
| Genentech | For profit | 1 | 0 | 1 | 2016 |
| Roche | For profit | 1 | 1 | 1 | 2017 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1